{"id":"aspirin-clopidogrel-celecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding/hemorrhage"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Thrombotic thrombocytopenic purpura (clopidogrel-related)"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation. Celecoxib selectively inhibits COX-2, providing anti-inflammatory and analgesic effects. Together, these agents provide dual antiplatelet therapy with added anti-inflammatory benefit.","oneSentence":"This combination inhibits platelet aggregation through multiple pathways (cyclooxygenase and P2Y12 receptor blockade) while also reducing inflammation via COX-2 inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:19:04.279Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome or post-percutaneous coronary intervention (dual antiplatelet therapy with anti-inflammatory component)"}]},"trialDetails":[{"nctId":"NCT00152724","phase":"","title":"Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"1996-01","conditions":"Healthy Volunteers","enrollment":85},{"nctId":"NCT00882388","phase":"PHASE4","title":"The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT00778193","phase":"PHASE4","title":"Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers","status":"COMPLETED","sponsor":"Research Associates of New York, LLP","startDate":"2007-10","conditions":"Gastroduodenal Ulcer","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["aspirin : Keun-Hwa Phamaceutical","clopidogrel : sanofi-aventis","celecoxib : Pfizer"],"phase":"marketed","status":"active","brandName":"aspirin + clopidogrel + celecoxib","genericName":"aspirin + clopidogrel + celecoxib","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits platelet aggregation through multiple pathways (cyclooxygenase and P2Y12 receptor blockade) while also reducing inflammation via COX-2 inhibition. Used for Acute coronary syndrome or post-percutaneous coronary intervention (dual antiplatelet therapy with anti-inflammatory component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}